Drug details:
Molecular formula: C₂₄H₁₈F₃N₃O₃S₂

Standard name: 2-[(4-methylphenyl)sulfonylamino]-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide

Synonyms:

2-[(4-methylphenyl)sulfonylamino]-n-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide 2-(4-Methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide 2-((4-methylphenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide

Curated SMILES: CC1=CC=C(S(=O)(=O)NC2=C(C(=O)NC3=NC(C4=CC=CC=C4)=CS3)C=CC(C(F)(F)F)=C2)C=C1

Evidence for compound's anti-virulence activity:

Klebsiella
Related VFcategory: Biofilm; Biofilm
Target: Not determined
Drug effect: Blocks AI-2 signaling response and inhibits biofilm formation.
Max phase: Preclinical (in vivo)
Publication:
Zhang Y, et al., 2022. ML364 exerts the broad-spectrum antivirulence effect by interfering with the bacterial quorum sensing system. Front Microbiol 13:980217.

Pseudomonas
Related VF: Pyocyanin
Target: PctA;TlpQ
Drug effect: Attenuates the biofilm formation and inhibits the productions of pyocyanin.
Max phase: Preclinical (in vivo)
Publication:
Zhang Y, et al., 2022. ML364 exerts the broad-spectrum antivirulence effect by interfering with the bacterial quorum sensing system. Front Microbiol 13:980217.

Staphylococcus
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Interferes with AI-2 of QS, the non-species-specific signaling molecule and attenuates the biofilm formation, production of staphyloxanthin .
Max phase: Preclinical (in vivo)
Publication:
Zhang Y, et al., 2022. ML364 exerts the broad-spectrum antivirulence effect by interfering with the bacterial quorum sensing system. Front Microbiol 13:980217.